Delegates will receive practical analysis and advice on:

• Astra Zeneca and the Commission’s Pharma Policy
• Market definition and dominance in the Pharma sector following Astra Zeneca
• Unilateral conduct – when does it risk infringing antitrust rules? A view from the EU and the US
• The EU and US approach to settlement agreements
• Roundtable: a follow up on the EU Inquiry at National level

Chairman and speakers include:

Stephen Kon, Partner, SJ Berwin LLP

Dominik Schnichels, Head of Pharma Task Force, DG Competition, European Commission

Mike Walker, Vice President, Charles River Associates

Marleen van Kerckhove, Partner, Arnold & Porter LLP

Asim Varma, Partner, Arnold & Porter LLP

Ingrid Vandenborre, Partner, Skadden Arps Slate Meagher & Flom LLP

Cameron Firth, Partner, SJ Berwin LLP

David Rosenberg, Vice President, Corporate IP Policy, GlaxoSmithKline

Gavin Robert, Partner, Linklaters LLP

Jeffrey Schmidt, Partner, Linklaters LLP

Melanie Thill Tayara, Partner, Norton Rose

Jordi Faus, Partner, Faus & Moliner Abogados

Thomas Wessely, Partner, Freshfields Bruckhaus Deringer LLP

Chairman: Stephen Kon, Partner, SJ Berwin LLP

09.00 Chairman’s opening remarks

09.10 Keynote Address
‘Astra Zeneca and the Commission’s Pharma Policy'
Dominik Schnichels, Head of the Pharma Task Force, DG Competition, European Commission

09.35 Market Definition and Dominance in the Pharma sector following Astra Zeneca – What does it mean for your company?

Market definition in the presence of innovation, patents and price regulation
Dominance: power over price vs. power to exclude
Mike Walker, Vice President, Charles River Associates

10.10 Coffee

10.30 Unilateral conduct – when does it risk infringing antitrust rules?
A view from the EU and the US
Use and misuse of regulatory procedures
Patent filing and patent enforcement
Product switching
Marleen van Kerckhove, Partner, Arnold & Porter LLP
Asim Varma, Partner, Arnold & Porter LLP

11.50 Roundtable Discussion and Q & A session

The speakers will be joined by
James S. Venit, Partner, Skadden Arps Slate Meagher & Flom LLP
Cameron Firth, Partner, SJ Berwin LLP
David Rosenberg, Vice President, Corporate IP Policy, GlaxoSmithKline

12.40 Lunch

14.00 EU and US Approach to Settlement Agreements
Recent legal developments
· FTC investigations and US court case law
· US legislative initiatives
· The EU Pharma inquiry, and follow up monitoring
· EU cases / investigations
Distinguishing the good from the bad
Future directions

Gavin Robert, Partner, Linklaters LLP
Jeffrey Schmidt, Partner, Linklaters LLP

15.10 Tea

15.30 Roundtable: A follow up on the EU Inquiry at National Level
Series of short presentations on a Member State by Member State basis
France: Melanie Thill Tayara, Partner, Norton Rose
Spain: Jordi Faus, Partner, Faus & Moliner Abogados
Germany:Thomas Wessely, Partner, Freshfields Bruckhaus Deringer LLP

16.50 Summing up and close

17.00 Close